| EPD494 | Triple R project support for HIV Exposed Infants adherence to HIV interval testing until end of exposure | E-poster | Prevention interventions and their effects on the lives and relationships of people living with HIV |
| PESUE17 | Triangulating orphans and vulnerable children program and health facility data to improve HIV treatment outcomes for children and adolescents living with HIV | Poster exhibition | Innovations and lessons for supporting HIV prevention effective use and treatment adherence |
| EPB043 | Trends in QGIT positivity among newly diagnosed people living with HIV in South Africa: results from the TEKO trial | E-poster | Tuberculosis: Prevention, diagnosis, treatment |
| OALBX0106 | Trends in PrEP inequity by race and census region, United States, 2012-2021 | Oral abstract session with live Q&A | Scale up of PrEP |
| EPC021 | Trends in pediatric HIV treatment continuity and the impact of COVID-19: a multi-country review of PEPFAR supported programs | E-poster | Epidemiology of HIV in infants and children |
| PEMOC48 | Trends in HIV viral load testing and viral suppression in US HIV cohort, 2017-2020 | Poster exhibition | Effects of the COVID-19 on HIV epidemiology and prevention |
| EPC225 | Trends in HIV post-exposure prophylaxis following sexual exposure (PEPSE) in Brazil (2011-2019) | E-poster | Scale up of PEP |
| EPC142 | Trends in HIV annual test uptake and retesting among gay and bisexual men and other men who have sex with men in Australia with no evidence of PrEP use between 2013-2021 | E-poster | Measuring and evaluating quality of service provision and health outcomes through public health surveillance |
| EPB040 | Treatment outcome of rifampicin-resistant tuberculosis among people with HIV in South Africa: a nested prospective cohort study | E-poster | Tuberculosis: Prevention, diagnosis, treatment |
| EPB147 | Treatment experience of single-tablet dolutegravir/lamivudine in the United States: results from the 'real-world outcomes with dolutegravir-based two-drug-regimens for the treatment of HIV-1' (TANDEM study) | E-poster | ART in acute, first- and second-line therapies |